Xenikos BV, of Nijmegen, the Netherlands, said researchers in the Netherlands and Germany have reported positive interim results of a phase I/II study with T-Guard for treatment of steroid-resistant, acute, graft vs. host disease. T-Guard is a combination of two toxin-loaded anti-T-cell antibodies that shows promise as a therapeutic tool for safely and swiftly resetting the body's immune system in T-cell mediated diseases, the company said.